Gut Liver.  2019 Nov;13(6):683-689. 10.5009/gnl18355.

Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment

Affiliations
  • 1College of Veterinary Medicine, Konkuk University, Seoul, Korea.
  • 2Center for Liver Cancer, Hospital, National Cancer Center, Goyang, Korea. wsm@ncc.re.kr, spark@ncc.re.kr
  • 3Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.
  • 4Center for Diagnostic Oncology, Hospital, National Cancer Center, Goyang, Korea.

Abstract

BACKGROUND/AIMS
Pancreatic ductal adenocarcinoma (PDA) is associated with an extremely poor prognosis. This study assessed the genetic diversity among patients with PDA and compared their mutational profiles before and after treatment.
METHODS
Tumors and matched blood samples were obtained from 22 PDA patients treated with neoadjuvant chemoradiation therapy. The somatic mutations were analyzed with comprehensive cancer gene panel (CCP). In addition, the biopsy samples obtained at diagnosis and the surgically resected samples after treatment were compared for seven patients. The CCP provided formalin-fixed paraffin-embedded sample-compatible multiplexed target selection for 409 genes implicated in cancer.
RESULTS
Assessments of the MLH1, MLH3, MSH2, and PMS2 genes showed that the four patients with the highest relative burdens of mutations harbored somatic mutations in at least three of these genes. Genes in the histone-lysine N-methyltransferase 2 (KMT2) family, such as KMT2D, KMT2A, and KMT2C, were frequently mutated in tumor samples. Survival was worse in patients with ARID1A gene mutations than those without ARID1A gene mutations. Mutation patterns were compared between tissue samples before and after neoadjuvant treatment in seven patients who underwent surgical resection. The allelic fraction of mutations in KRAS codon 12 was lower in the surgically resected samples than in the endoscopic ultrasonography-guided fine needle aspiration biopsy samples of six patients. The number of mutant alleles of the histone lysine methyltransferase gene WHSC1 also decreased after treatment.
CONCLUSIONS
These results indicate that tumor tissue from PDA patients is genetically diverse and suggest that ARID1A mutations may be a potential prognostic marker for PDA.

Keyword

Pancreatic neoplasms; ARID1A; Histone-lysine N-methyltransferase

MeSH Terms

Adenocarcinoma
Alleles
Biopsy
Biopsy, Fine-Needle
Codon
Diagnosis
Genes, Neoplasm
Genetic Variation*
Histone-Lysine N-Methyltransferase
Humans
Neoadjuvant Therapy*
Pancreatic Ducts
Pancreatic Neoplasms*
Prognosis
Codon
Histone-Lysine N-Methyltransferase
Full Text Links
  • GNL
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr